105.43 USD
-2.28
2.12%
At close Feb 14, 4:00 PM EST
After hours
105.43
+0.00
0.00%
1 day
-2.12%
5 days
-1.02%
1 month
6.10%
3 months
1.96%
6 months
-7.13%
Year to date
8.53%
1 year
6.44%
5 years
7.99%
10 years
3.11%
 

About: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Employees: 75,883

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

21% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 82

0% less funds holding

Funds holding: 1,294 [Q2] → 1,289 (-5) [Q3]

0.59% less ownership

Funds ownership: 6.64% [Q2] → 6.04% (-0.59%) [Q3]

2% less capital invested

Capital invested by funds: $15.5B [Q2] → $15.2B (-$258M) [Q3]

13% less funds holding in top 10

Funds holding in top 10: 15 [Q2] → 13 (-2) [Q3]

15% less repeat investments, than reductions

Existing positions increased: 405 | Existing positions reduced: 474

42% less call options, than puts

Call options by funds: $171M | Put options by funds: $294M

Research analyst outlook

We haven’t received any recent analyst ratings for NVS.

Financial journalist opinion

Based on 22 articles about NVS published over the past 30 days

Positive
Seeking Alpha
16 hours ago
Novartis: Strong Execution With A P/E Discount
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation, supportive dividend yield, and ongoing buyback make it a buy. The company also trades below its peer average multiple.
Novartis: Strong Execution With A P/E Discount
Positive
Seeking Alpha
2 days ago
Novartis: Just What The Doctor Ordered
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield.
Novartis: Just What The Doctor Ordered
Positive
Proactive Investors
5 days ago
Novartis to buy Anthos Therapeutics in $3.1bn deal
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion.
Novartis to buy Anthos Therapeutics in $3.1bn deal
Positive
Reuters
5 days ago
Novartis agrees to acquire Anthos for up to $3.1 bln
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Novartis agrees to acquire Anthos for up to $3.1 bln
Neutral
Business Wire
5 days ago
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Neutral
GlobeNewsWire
5 days ago
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Positive
Zacks Investment Research
1 week ago
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
Positive
Zacks Investment Research
1 week ago
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
1 week ago
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Novartis (NVS) is a Strong Value Stock
Positive
The Motley Fool
1 week ago
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Charts implemented using Lightweight Charts™